How to achieve a predictable basal insulin?

Diabetes and Metabolism

Volumn 31, Issue 4 II, 2005, Pages

  Kurtzhals, P ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Albumin binding; Insulin analogues; Variability

Indexed keywords

ACETYLSALICYLIC ACID; CARRIER PROTEIN; DIAZEPAM; FATTY ACID; GLIBENCLAMIDE; IBUPROFEN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING DRUG; PHENYLBUTAZONE; SERUM ALBUMIN; SOMATOMEDIN C; TOLBUTAMIDE; VALPROIC ACID; WARFARIN; ZINC ION;

AQUEOUS SOLUTION; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; HUMAN; HYPOGLYCEMIA; MITOGENESIS; NONHUMAN; REVIEW;

EID: 25444441553     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(05)88264-3     Document Type: Review

References (56)

1. Home P. The challenge of poorly controlled diabetes mellitus. Diabetes Metab 2003;29:101-9.
2. Kruszynska YT, Home PD, Hanning I, Alberti KGMM. Basal and 24-h C-peptide and insulin secretion in normal man. Diabetologia 1987;30:16-21.
3. Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-9.
4. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am 1997;26:599-610.
5. Emdin SO, Dodson GG, Cutfield JM, Cutfield SM. Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic β-cell. Diabetologia 1980;19:174-82.
6. Kang S, Brange J, Birch A, et al. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 1991;14:942-8.
7. Hildebrandt P, Sejrsen P, Nielsen SL, Birch K, Sestoft L. Diffusion and polymerisation determine the insulin absorption from subcutaneous tissue in diabetic patients. Scand J Clin Lab Invest 1985;45:685-90.
8. Brange J, Ribel U, Hansen JF, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988;333:679-82.
9. De Meyts P. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 1994;37:S135-48.
10. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54.
11. Brange J, Volund AA. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999;35:307-35.
12. Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001;109:S317-32.
13. Gualandi-Signorini AM, Giorgi G. Insulin formulations - a review. Eur Rev Med Pharmacol Sci 2001;5:73-83.
14. Jørgensen LN, Dideriksen LH, Drejer K. Carcinogenic effect of human insulin analogue B10Asp in female rats. Diabetologia 1992;35: A3 [abstract].
15. Hansen BF, Danielsen GM, Drejer R, et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996;315:271-9.
16. Kurtzhals P, Schäffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005.
17. Lauritzen T, Pramming S, Gale EA, Deckert T, Binder C. Absorption of isophane (NPH) insulin and its clinical implications. Br Med J 1982;285:159-62.
18. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull 1991;38:337-46.
19. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-82.
20. Chen JW, Christiansen JS, Lauritzen T. Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab 2003;5:223-33.
21. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagedorn (XPH) insulin in pens. Lancet 1999;354:1604-7.
22. Owens D, Zinman B, Bolli G. Insulins today and beyond. Lancet 2001;358:739-46.
23. McAulay V, Frier BM. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003;4:1141-56.
24. 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-9.
25. Soltesz G. Hypoglycaemia in the diabetic child. Baillieres Clin Endocrinol Metab 1993;7:741-55.
26. Gonder-Frederick LA, Clarke WL, Cox DJ. The emotional, social, and behavioral implications of insulin-induced hypoglycemia. Semin Clin Neuropsychiatry 1997;2:57-65.
27. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002;16:47-92.
28. Markussen J, Hougaard P, Ribel U, Sørensen AR, Sørensen E. Soluble, prolonged-acting insulin derivatives. I: Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B23, B27 and B30. Protein Eng 1987;1:205-13.
29. Markussen J, Diers I, Engesgaard A, et al. Soluble, prolonged-acting insuln derivatives II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. Protein Eng 1987;1:215-23.
30. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise TI. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.
31. Kurtzhals P., Ribel U. Action profile of cobalt(III)-insulin: a novel principle of protraction of potential use for basal insulin delivery. Diabetes 1995;44:1381-5.
32. 3+-insulin hexamer is a prolonged-acting insulin prodrug. J Pharm Sci 1995;84:1164-8.
33. Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312:725-31.
34. Markussen J, Havelund S, Kurtzhals P, et al. Soluble fatty acid insulins bind to albumin and show protracted action in pigs. Diabetologia 1996;39:281-8.
35. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004;21:1498-504.
36. Whittingham JL, Havelund S, Jonassen I. Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry, 1997;36:2826-31.
37. Kutzhals P, Colding-Jorgensen M. Albumin binding of insulin detemir reduces the risk for hypoglycaemic events. Diabetes 2004;53: A477 [abstract 1995-PO].
38. Hamilton-Wessler M, Ader M, Dea M, et al. Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin. Diabetologia 1999;42:1254-63.
39. Hamilton-Wessler M, Ader M, Dea MK, et al. Mode of capillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion. Diabetes 2002;51:574-82.
40. Dea MK, Hamilton-Wessler M, Ader M, et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 2002;51:762-9.
41. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004;28:S23-8.
42. Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 1997;86:1365-8.
43. Sorensen AR, Tornqvist H. Effects of insulin detemir on glucose uptake and utilisation in human and rat adipocytes. Diabetes 2004;53: A558 [abstract 2355-PO].
44. Pieber TR, Plank J, Goerzer E, et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 2002;51:A53 [abstract].
45. Heise T, Nosek L, Billmann Ronn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.
46. Danne T, Lüpke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterised by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-92.
47. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36.
48. Standl E, Lang H, Roberts A, et al. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 2004;6:579-88.
49. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.
50. De Leeuw I, Selam JL, Skeie S, Elte JWF, Lang H, Vague P. Insulin detemir-based used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-83.
51. Home P, Bartley P, Russell-Jones D, et al., on behalf of the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27:1081-7.
52. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9.
53. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
54. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
55. Kolendorf K, Pavlic-Renar I, Santeusanio F, Philotheou A, Gall MA, Heller C. Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with type 1 diabetes. Diabetes 2004;53:A130-131 [abstract 551-P].
56. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-70.